Truist Financial Forecasts Strong Price Appreciation for Integer (NYSE:ITGR) Stock

Integer (NYSE:ITGR) had its price target lifted by research analysts at Truist Financial from $97.00 to $110.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price would indicate a potential upside of 11.83% from the company’s previous close.

ITGR has been the topic of several other research reports. Zacks Research cut Integer from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. Piper Sandler reissued an “overweight” rating and issued a $97.00 price objective (up from $87.00) on shares of Integer in a research report on Friday, May 1st. Finally, Citigroup raised their target price on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $101.14.

Integer Stock Up 2.9%

Shares of ITGR stock traded up $2.81 during trading hours on Thursday, hitting $98.36. 104,774 shares of the company were exchanged, compared to its average volume of 651,529. The company has a market capitalization of $3.34 billion, a PE ratio of 24.52, a PEG ratio of 2.22 and a beta of 0.64. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77. Integer has a 52 week low of $62.00 and a 52 week high of $117.58. The business has a 50 day moving average of $91.15 and a two-hundred day moving average of $87.30.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.01). The firm had revenue of $439.58 million during the quarter, compared to analyst estimates of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.31 EPS. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. Analysts anticipate that Integer will post 6.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ITGR. EverSource Wealth Advisors LLC raised its holdings in shares of Integer by 48.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 117 shares during the period. Salomon & Ludwin LLC raised its stake in Integer by 46.8% in the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 118 shares during the period. Harbor Investment Advisory LLC acquired a new position in Integer in the 2nd quarter valued at about $42,000. TD Private Client Wealth LLC grew its position in shares of Integer by 1,037.5% in the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 415 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Integer by 135.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 267 shares during the period. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.